27Jul/17

Gilead’s hepatitis C franchise breaks out of a rut, but the M&A drumbeat continues

Gilead Sciences made an unexpected turnabout in the second quarter, with hepatitis C sales finding firmer ground after a long slog through quarter after quarter of slough. The hep C franchise, whichRead More…

26May/17

Increasing Flurry of FDA Orphan Drug Development Activity Fueling Uptick of Enthusiasm for Few Pharma Stocks

The healthcare sector which includes biotech, pharmaceutical, and medical device stocks, continues to forge ahead despite recent concerns in the markets as some of the larger companies show attractive earnings growth potentialRead More…

06Apr/17

Biotech, the New ‘Fire’

We suspect that somewhere around the Stone Age, our African ancestors learned to do something that would change the evolutionary cycle of humanity; they learned to control fire. I can’t imagine theRead More…